BioCentury | Jun 15, 2018
Clinical News

Elios' dendritic cell vaccine leads to no significant difference in recurrence in Phase IIb for melanoma

...care (SOC) therapies, with inoculations given at 0, 1, 2, 6, 12 and 18 months. Elios Therapeutics LLC...
...disease-free survival (DFS) Status: Interim Phase IIb data Milestone: NA Jaime De Leon American Society of Clinical Oncology ASCO Elios Therapeutics LLC TLPLDC...
Items per page:
1 - 1 of 1
BioCentury | Jun 15, 2018
Clinical News

Elios' dendritic cell vaccine leads to no significant difference in recurrence in Phase IIb for melanoma

...care (SOC) therapies, with inoculations given at 0, 1, 2, 6, 12 and 18 months. Elios Therapeutics LLC...
...disease-free survival (DFS) Status: Interim Phase IIb data Milestone: NA Jaime De Leon American Society of Clinical Oncology ASCO Elios Therapeutics LLC TLPLDC...
Items per page:
1 - 1 of 1